[Clinical value of changes in red blood cell ultrastructure and energy metabolism in children with cystic fibrosis].

In 42 patients of various age (from 1 month to 14 years) with cystic fibrosis were analyzed ultra structure, level of adenylnucleotides and activity ATP-ase of erythrocytes, in order to characterize their membrane and energy metabolism. The studies revealed the changes in erythrocytes in the cases of cystic fibrosis. In the cases of broncho pulmonary form of cystic fibrosis were detected I and II row echinocytes, cone-shaped erythrocytes, also erythrocytes with reach-through hole in center. At mixed form of cystic fibrosis were detected more changes in erythrocytes than in other forms of this disease. Both cone-shaped erythrocytes were more than in other forms of cystic fibrosis. Also there were detected erythrocytes with holes (round, polygonal) in their center. The results of the study provide a more precise diagnosis, in time correction of disorders and a comprehensive assessment of multiple-modality treatment of cystic fibrosis.

Treatment of aggressive non-Hodgkin's lymphomas.

The aim of the study was to evaluate overall survival in patients with diagnosis DLBCL, comparing CHOP chemotherapy plus rituximab with CHOP alone, and standard plus intensive regimens (BEAM). Above mentioned regimens were compared in high risk patient, who were identified according to the CD10 expression with factors of IPI. 27 patients with diagnosis of diffuse large B-cell lymphomas were under observation. CD20 expression was assessed in all cases. Overall survival therapy was compared in three groups. I- primary refractory patients who undergone chemotherapy with CHOP regimen (9 patents); II - patients refractory to the standard added intensive chemotherapy regimens (BEAM) (10 patients). III - patients who were treated with combination CHOP plus rituximab (8 patients); As it shown on the figure overall survival was the highest in III group and composes 17 months, as for II and I groups overall survival was 7,4 and 8,8 months respectively. In summary based on our observations quantity of unfavorable prognostic factors may determine primary refractory patients to standard therapies and first line treatment in CD20 positive cases with CHOP plus Rituximab regimen increased overall survival from 7,4 month to 17 month (p<0,01).